Associated tags: Patient, Fear, SAN, Cancer, Pharmaceutical industry, Research, Medical imaging, Health, LHN, Precision medicine
Locations: PENNSYLVANIA, SAN FRANCISCO, CA, US, CHICAGO, MISSOURI, UNITED STATES, NORTH AMERICA, CANADA, WA
Retrieved on:
Tuesday, December 5, 2023
RWD,
COVID-19,
OCE,
Fear,
Research,
Lung cancer,
MD,
SAN,
Cancer,
Patient,
LHN,
Safety,
RWE SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, and the FDA Oncology Center of Excellence (OCE) renewed a four-year agreement to collaboratively develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) to inform regulatory objectives.
Key Points:
- SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, and the FDA Oncology Center of Excellence (OCE) renewed a four-year agreement to collaboratively develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) to inform regulatory objectives.
- This collaboration specifically aims to evaluate RWD study designs and analytic methods, and to develop clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.
- “Our early work with the FDA Oncology Center of Excellence evaluated safety and health disparities through the lens of RWD,” said Thomas Brown, MD, Chief Medical Officer at Syapse.
- “Specifically, we analyzed real-world immune-checkpoint inhibitor-related pneumonitis in lung cancer and were one of the first to respond to assess the impact of Covid-19 on cancer patients during the pandemic.
Research,
Machine learning,
AACR,
Health,
ISPOR,
Breast cancer,
American Medical Informatics Association,
SAN,
Real,
Pharmacotherapy,
Patient,
Biosimilar,
Fear,
Disease,
RWE,
ASCO,
AMIA,
Diagnosis,
Informatics,
RWD,
Knowledge management,
Health information management,
Medical device,
Nursing,
Pharmaceutical industry Syapse will be presenting at the American Medical Informatics Association (AMIA) Informatics Summit being held March 13-16 in Seattle, WA.
Key Points:
- Syapse will be presenting at the American Medical Informatics Association (AMIA) Informatics Summit being held March 13-16 in Seattle, WA.
- "We are thrilled to present the results of our custom research at the AMIA Informatics Summit," said Vinod Subramanian, Chief Product and Data Officer.
- Subramanian added, "We are excited to continue our research and work with healthcare providers to further develop and refine our AI-based capabilities.
- In addition to presenting this research at AMIA, Syapse will be attending ISPOR, ASCO, and AACR.
Retrieved on:
Thursday, September 15, 2022
MSD,
Cancer,
SAN,
RWD,
Collaboration,
NEW,
CEO,
GLOBE,
Data,
Health,
Merck,
Fear,
Diagnosis,
Patient,
Pharmaceutical industry This agreement continues a longstanding collaboration between Merck and Syapse and is a testament to the growing power of real-world evidence and the position that Syapse has established as a leader in the oncology space, said Ken Tarkoff, CEO of Syapse.
Key Points:
- This agreement continues a longstanding collaboration between Merck and Syapse and is a testament to the growing power of real-world evidence and the position that Syapse has established as a leader in the oncology space, said Ken Tarkoff, CEO of Syapse.
- Merck will utilize Syapses real-world data platform across multiple tumor types with a focus on better understanding the critical stage in the patient journey leading up to a diagnosis and beginning treatment.
- Syapses network enables improved cancer care through collaboration and real-world evidence.
- Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care.
Retrieved on:
Wednesday, August 31, 2022
Communication,
Partnership,
Biomarker,
Genesis,
Research,
CEO,
Cancer,
Strategic planning,
Fear,
Industry,
GLOBE,
SAN,
Patient,
Medical imaging Pharmaceutical and biotech companies partner with Genesis Research to conduct real-world evidence-based research that supports the development and launch of new and innovative treatments.
Key Points:
- Pharmaceutical and biotech companies partner with Genesis Research to conduct real-world evidence-based research that supports the development and launch of new and innovative treatments.
- Concurrently, this strategic relationship will enable Syapse to provide its clients with streamlined access to Genesis unique, integrated, fit-for-purpose research partnerships.
- Syapse and Genesis Research are a fantastic complement to each others strengths, focuses, and missions, said Ken Tarkoff, CEO of Syapse.
- Genesis Research is an international health economics and outcomes research and real-world evidence research organization that supports the life sciences industry.
ASCO,
Fear,
GLOBE,
Social capital,
SAN,
RWE,
Research,
Solution,
American Society of Clinical Oncology,
Cancer,
Machine learning,
Biotechnology,
Technology,
Patient,
Precision medicine,
NEW,
Pete Musser,
LLC,
Society,
Pharmaceutical industry,
Management,
Medicine,
Leymus innovatus The investment is led by an affiliate of Innovatus Capital Partners, LLC (Innovatus) , with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.
Key Points:
- The investment is led by an affiliate of Innovatus Capital Partners, LLC (Innovatus) , with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.
- Innovatus Capital Partners, LLC, is an independent adviser and asset management firm with approximately $1.7B in assets under management.
- The firm has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences.
- To date the Innovatus Life Sciences Strategy has made over $1.1B in capital commitments for debt and equity support.
Software,
Biotechnology,
Oncology,
Health,
Data Management,
Health Technology,
Technology,
Genetics,
Fear,
MBA,
Genomics,
Genetics,
CBO,
Oncology,
Precision medicine,
Cancer,
MD,
LHN,
Health,
Biomarker,
Partnership,
Patient,
Genetic testing,
AdventHealth,
Pharmaceutical industry,
Medical imaging,
Medicine,
Central Florida At Pierian we are laser focused on driving clinical adoption of next-generation sequencing worldwide, said Lindsay Mateo, CBO of Pierian.
Key Points:
- At Pierian we are laser focused on driving clinical adoption of next-generation sequencing worldwide, said Lindsay Mateo, CBO of Pierian.
- Our collaboration with AdventHealth and Syapse allows patients in Central Florida to benefit from local, comprehensive genomic testing supported by Pierian.
- Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.
- Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care.
Biomarker,
NGS,
Precision medicine,
Program,
MBA,
CEO,
Partnership,
Solution,
Health,
GLOBE,
Patient,
Genetics,
Genetic testing,
Oncology,
SAN,
MD,
Industry,
AdventHealth,
Genomics,
Fear,
LHN,
Cancer,
Medical imaging,
Medicine,
Pierian Spring,
Central Florida Pierian partners with clinicians and medical facilities worldwide to establish high-quality clinical genomics programs and a global sharing network.
Key Points:
- Pierian partners with clinicians and medical facilities worldwide to establish high-quality clinical genomics programs and a global sharing network.
- Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care.
- Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.
- With advanced interpretation technology connected to the most comprehensive genomic knowledge base, Pierian empowers providers with genomic insights to fulfill the promise of precision care.
EHR,
Disease,
Fear,
Patient,
Solution,
Society,
Metastasis,
Research,
Efficiency,
SAN,
ASCO,
Machine learning,
Precision medicine,
Cancer,
Myelodysplastic syndrome,
Health information management,
American Society of Clinical Oncology,
MD,
GLOBE,
Medical device,
Medical imaging Syapse will be presenting at the American Society for Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022 in Chicago.
Key Points:
- Syapse will be presenting at the American Society for Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022 in Chicago.
- This years ASCO is centered on a theme of innovation to make cancer care more equitable, convenient and efficient.
- This research demonstrates an accurate and scalable cancer metastasis classification method by leveraging machine learning models using EHR data.
- These cutting-edge data science methods with high volume health care data facilitates the delivery of precision oncology at scale.
Organization,
Board,
NYSE,
The Advisory Board Company,
Cros,
Health care,
Fear,
Research,
Biotechnology,
SAAS,
Board of directors,
CEO,
PricewaterhouseCoopers,
EVH,
The Co Founder,
Technology,
GLOBE,
SAN,
FDA,
Management Additionally, the company announced that it has named biopharmaceutical strategic advisor Michael Mentesana as its newest board member.
Key Points:
- Additionally, the company announced that it has named biopharmaceutical strategic advisor Michael Mentesana as its newest board member.
- We are excited to highlight Frank Williams valuable expertise by elevating his role on the board as we welcome the strategic counsel and guidance that Michael Mentesana will surely bring to his role as a board member, said Ken Tarkoff , CEO, Syapse.
- Frank previously served as Chairman and CEO of The Advisory Board Company, a research and SAAS technology firm with over 5,000 Healthcare customers worldwide.
- Frank has also served as an advisor and board member to numerous healthcare services/technology companies and has been a valued Director on the Syapse board since 2018.
Thought,
Main Line Health,
GLOBE,
Mainline,
Health,
Fear,
SAN,
RWD,
Oncology,
Patient,
LHN,
CEO,
Clinical trial,
Pharmaceutical industry,
Medical imaging Main Line Health will utilize the Syapse multi-source real-world data (RWD) platform to match patients in the Philadelphia region to potentially life-saving clinical trial opportunities.
Key Points:
- Main Line Health will utilize the Syapse multi-source real-world data (RWD) platform to match patients in the Philadelphia region to potentially life-saving clinical trial opportunities.
- Main Line Health is focused on providing care that leverages the forefront of oncology innovation in cancer therapies and care coordination technologies.
- Our unmatched expertise in the community health care setting makes this a natural collaboration for both parties and we look forward to working with Main Line Health to bring Philadelphia region patients access to life-saving clinical trial opportunities.
- Leveraging the LHN, healthcare providers can learn which cancer treatments produced the best real-world outcomes in clinically and molecularly similar patients.
